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Background:
During
inflammation,
myeloperoxidase (MPO) accumulates within the
subendothelial matrix and produces the reactive
oxidant hypochlorous acid (HOCl).
Results: Subendothelial MPO catalyzes focal,
HOCl-mediated matrix oxidation that disrupts
cell-matrix adhesion and alters adhesiondependent cell signaling.
Conclusion: MPO disrupts endothelial integrity
and promotes cell signaling by targeted
subendothelial matrix oxidation.
Significance: MPO-mediated matrix oxidation has
important implications for endothelial integrity
and function during inflammation.

cells (de-adhesion). This de-adhesion was linked
with the alteration of Tyr-118 phosphorylation
of paxillin, a key focal adhesion-dependent
signaling process, as well as Rho kinasedependent
myosin
light
chain-2
phosphorylation. De-adhesion dynamics were
dependent on the contractile state of cells, with
myosin II inhibition with blebbistatin markedly
attenuating the rate of membrane retraction.
Rho kinase inhibition with Y-27632 also
conferred protection, but not during the initial
phase of membrane retraction, which was
driven by pre-existing actomyosin tensile stress.
Notably, diversion of MPO from HOCl
production by thiocyanate and nitrite
attenuated de-adhesion and associated signaling
responses, despite the latter substrate
supporting
MPO-catalyzed
fibronectin
nitration. This study indicates that HOClmediated matrix oxidation by subendothelial
MPO deposits may play an important and
previously unrecognized role in altering
endothelial adhesion, signaling and integrity
during inflammatory vascular disorders.

SUMMARY
During inflammation, myeloperoxidase (MPO)
released by circulating leukocytes accumulates
within the subendothelial matrix by binding to
and transcytosing the endothelium. Oxidative
reactions catalyzed by subendothelial-localized
MPO are implicated as a key cause of
endothelial dysfunction in inflammatory
vascular diseases. Whilst the subendothelial
matrix is a reactive target for MPO-derived
oxidants in disease, the functional implications
of oxidative matrix modification for the
endothelium are largely unknown. Here we
show that hypochlorous acid (HOCl) produced
by endothelial-transcytosed MPO oxidizes the
subendothelial matrix, involving covalent
crosslinking of the adhesive matrix protein
fibronectin. Real-time biosensor and live cell
imaging studies showed that HOCl-mediated
matrix oxidation triggers rapid membrane
retraction from the substratum and adjacent

The vascular endothelium performs vital functions
in cardiovascular homeostasis by regulating the
initiation and resolution of inflammatory
responses and by controlling vascular tone. An
important function of the endothelium in this
regard is its production of nitric oxide (NO),
which exerts anti-inflammatory actions by
inhibiting leukocyte adhesion, inhibits platelet
aggregation and regulates vascular tone by
signaling for vasodilation in the adjacent vascular
smooth muscle cells (1). The homeostatic
1
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oxidation of chloride ions (Cl-) in the presence of
the co-substrate hydrogen peroxide (H2O2)
(17,18). Thiocyanate (SCN−) and nitrite (NO2−) are
also significant physiological substrates that divert
the enzyme from HOCl production to the
generation of the thiol-reactive oxidant
hypothiocyanous acid (HOSCN) and the nitrating
radical nitrogen dioxide (NO2), respectively (18).
Various studies support that subendothelial matrix
proteins are significant oxidative targets for MPOderived oxidants. Thus, MPO transcytosed by
cultured endothelial cells binds to adhesive matrix
substrate fibronectin, conferring specificity of
MPO-catalyzed tyrosine nitration to this protein
(12). In atherosclerotic coronary arteries and other
inflamed vascular tissue from humans, MPO is
characteristically found deposited within the
subendothelium where it co-localizes with
fibronectin-containing extracellular matrix and
tyrosine-nitrated proteins (19). Extracellular
deposits of MPO and HOCl-modified proteins are
similarly detected within the vascular endothelium
of human atherosclerotic arteries (20,21).
While
oxidative
modification
of
subendothelial matrix proteins by MPO-derived
oxidants is a characteristic event during
inflammatory vascular disease, the implications of
this for endothelial cell morphology, signaling and
phenotype are largely unknown. In the current
study, we show that endothelial-transcytosed MPO
mediates HOCl-dependent subendothelial matrix
oxidation, involving covalent crosslinking of
fibronectin, and that this triggers cell-matrix deadhesion driven by actomyosin-dependent tensile
stress. We provide evidence that de-adhesion in
response to HOCl-mediated matrix oxidation
drives changes in key adhesion-dependent
signaling processes and that diversion of MPO
from HOCl production by SCN− or NO2−
attenuates de-adhesion and associated signaling
responses, despite the latter supporting MPOcatalyzed matrix nitration. The ability of
transcytosed MPO to disrupt endothelial integrity
by targeted, HOCl-mediated subendothelial matrix
oxidation may have important implications for the
regulation of endothelial signaling and function
during inflammation.

properties of the endothelium are also dependent
on its function as a continuous, semi-permeable
barrier that tightly regulates the passage of
nutrients, macromolecules, fluid and cells between
the blood and the interstitial space (2,3).
Inflammatory vascular diseases such as
atherosclerosis are characterized by endothelial
dysfunction manifested as a reduction in the
bioactivity of endothelial-derived NO (1) and a
loss of endothelial barrier integrity leading to
endothelial hyper-permeability (4,5). Enhanced
vascular oxidative stress during inflammation is
implicated as a principal cause of compromised
endothelial NO signaling (1) and barrier function
(2,3) and accordingly there is significant interest in
understanding the oxidative reactions involved.
Considerable clinical and experimental
evidence supports that myeloperoxidase (MPO),
an oxidant-generating heme enzyme released by
activated leukocytes, plays a pathogenic role in
impairing the signaling and vasodilatory function
of endothelium-derived NO during inflammatory
vascular disease. Thus, circulating MPO levels are
elevated in coronary artery disease patients and the
extent of this increase is an independent predictor
of the incidence of endothelial dysfunction
manifested as impaired endothelium-dependent
vasorelaxation (6,7), as well as the prevalence and
degree of coronary artery disease and clinical
event risk in patients with acute coronary
syndromes (8,9). Inflammatory stimuli that
increase circulating MPO levels promote
endothelial dysfunction in healthy animals and
humans, with a deficiency in functional MPO
conferring protection (10,11). Intravascular
administration of MPO also impairs endothelialdependent vasorelaxation (11). Circulating MPO
rapidly leaves the circulating compartment by
binding to and transcytosing the endothelium,
resulting in its accumulation within the
subendothelial matrix, where it is anatomically
positioned to impair the signaling and vasodilatory
function of endothelium-derived NO by acting as a
NO oxidase (10,12,13).
Subendothelial-localized MPO is not only
positioned to interfere with NO signaling, but to
generate reactive oxidants capable of altering the
structure and function of extracellular matrix
proteins (12,14-16). The potent chlorinating
oxidant hypochlorous acid (HOCl) is the principal
oxidant produced by MPO and is generated by
2
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EXPERIMENTAL PROCEDURES

37C, with subsequent washing) prior to the
seeding of cells. For surface binding of proteins,
volumes were selected to ensure uniformity of
protein coating, expressed relative to the adhesion
area of cells (i.e. g protein/mm2; 1 ml for 12-well
plates, 80 l for 96-well plates). ECs adhered to
fibronectin or MPO-bearing fibronectin coated
surfaces were then subjected to experimental
treatments in the same manner as described above
for ECs containing transcytosed MPO.
For experiments to measure the propensity
of ECs to adhere to fibronectin-bound surfaces
previously exposed to MPO-derived oxidants,
surfaces with MPO-bearing fibronectin were first
treated with oxidants in the same manner as MPOcontaining ECs (see above). Oxidant-exposed
surfaces were then incubated with Met (10 mM)
for 10 min to quench residual reactive, surfacebound protein chloramines followed by washing,
seeding of ECs and measurement of cell adhesion
by cell substrate impedance.

Cell culture— Bovine aortic endothelial cells
(ECs, Lonza; passages 4 - 9) were cultured in
EBM-2 medium (Lonza) and routinely passaged
on gelatin-coated tissue culture flasks.
Cell Experiments— For experiments with ECs
containing transcytosed MPO, ECs were initially
cultured to confluence in EBM-2 medium (Lonza;
with hydrocortisone omitted) on gelatin (Sigma;
coated at 100 g/ml in PBS, 20 min, 22C).
Confluent EC monolayers were then incubated for
2 h with 20 nM purified human neutrophil MPO
(Calbiochem) in HBSS supplemented with 0.2%
BSA, culture conditions that permit maximal
endothelial transcytosis of MPO (12,22). ECs
containing transcytosed MPO were washed to
remove unincorporated enzyme and then
incubated in HBSS in the absence or presence of
relevant reaction components including 1 mM
methionine (Met), 100 μM 4-aminobenzoic acid
hydrazide (ABAH), 100 μM SCN− and/or 100 μM
NO2− for 15 min, or with cell signaling inhibitors
(20 μM PP2, 40 μM blebbistatin, 10 μM Y-27632)
for 30 min, prior to treatment with H2O2 (2 - 50
μM) for up to 1 h. In some experiments, cells were
treated with reagent HOCl added as a bolus. H2O2
and HOCl solutions were prepared immediately
before use and stock concentrations were
determined spectrophotometrically (H2O2, ε240
43.6 M-1 cm-1; HOCl, ε292 350 M-1 cm-1 at pH 12).
For oxidant treatments, volumes were selected to
ensure uniformity of oxidant exposure expressed
relative to the adhesion area of cells (i.e. 1 ml for
12-well plates, 80 l for 96-well plates).
For experiments with ECs adhered to
fibronectin as the sole adhesive substrate, surfaces
were first coated with bovine fibronectin (Sigma;
5 g/ml / 22.7 nM in PBS, 2 h, 37C) and then
blocked with BSA (0.2% in PBS, 0.5 h, 37C)
prior to seeding of cells in serum-free media
(medium-199 containing 1% BSA; 1 ml at 5  105
cells/ml in 12-well plates, 200 l at 2.5  105
cells/ml in 96-well plates). These cell seeding
densities yielded a near-confluent layer of
adherent cells within 2 h. In experiments to
examine a role for fibronectin-bound MPO on EC
adhesion, MPO was first bound to fibronectincoated surfaces (20 nM MPO in HBSS, 0.5 h,

Experiments with purified fibronectin— Purified
bovine fibronectin (Sigma; 100 nmol/L, twice
desalted on PD MiniTrap G-25 columns, GE
Healthcare) was oxidized by pre-incubation with
MPO (100 nM) for 15 min and exposure to H2O2
(2 - 50 μM) for 1 h in the presence and absence of
1 mM Met, 100 μM, ABAH, 100 μM SCN− or 100
μM NO2−.
Real time quantification of cell adhesion by cellsubstrate impedance— Cell-substrate impedance
at the surface of 96-well gold microelectrode
arrays (E-plate 96®, Roche), expressed as ‘cell
index’, a dimensionless value proportional to the
area of cell-substrate contact (24), was measured
continuously following seeding of ECs and
subsequent treatments by an xCelligence® system
(Roche). During measurements, electrode arrays
were housed in an incubator port maintained at
37°C with 5% CO2 saturation. The relative number
of attached ECs on electrode surfaces was
quantified by crystal violet staining, as previously
detailed (16).
Live cell imaging— Differential interference
contrast (DIC) images of live cells on gelatin- or
fibronectin-coated 35mm glass-bottomed culture
dishes (Fluorodish, World Precision Instruments)
3
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conjugated goat anti-mouse (green) and Cy3conjugated donkey anti-rabbit (red) antibodies
were employed as secondary antibodies. Cell
nuclei were stained with DAPI (1:2000) and Factin was stained with Alexa 555-phalloidin
(Invitrogen; 1:500). After washing with PBS, cells
were mounted in Elvanol (Mowiol 4-88, Hoechst,
Frankfurt, Germany). Laser confocal fluorescence
images were recorded at room temperature using a
63 oil objective on a Leica TCS SP5 microscope.
Reconstructions of confocal images were rendered
using Imaris software.

were recorded at 37C on a heated stage at 5 s
intervals using a 63 water objective on a Leica
TCS SP5 microscope. The projected area of
randomly selected cells was quantified by
manually tracing the membrane edge and
quantifying the number of enclosed pixels using
ImageJ (NIH). Change in area of individual cells
over time was fitted to a single exponential decay
using non-linear regression (least squares fitting;
Prism 5, GraphPad Software) to determine the
half-life of cell contraction.
Measurement of H2O2— Cellular metabolism of
exogenously added H2O2 was measured using an
Amplex Red kit according to the manufacturer’s
instructions (Molecular Probes).

Statistics— Statistical analyses were performed
using one-way ANOVA with Newman Keul’s
post-hoc testing with Prism 5 software. Statistical
significance was accepted for p values <0.05.

Western blotting— Following experiments, cell
proteins and purified proteins were immediately
harvested into reducing loading buffer. Proteins
were separated on 3-8% Tris/Acetate NuPAGE®
gels or 10% Bis/Tris NuPAGE® gels (Invitrogen),
electroblotted to nitrocellulose (iBlot, Invitrogen)
then probed with mouse monoclonal antibodies
against fibronectin (1:2000; clone E3E, Millipore),
HOCl-oxidized protein (1:25; cell supernatant,
clone 2D10G9) (23), Src (1:1000; BD
Biosciences), paxillin (1:1000: Cell Signaling),
FAK (1:1000; Cell Signaling), and phospho-FAK
Tyr-397 (1:1000; BD Biosciences) or with rabbit
polyclonal antibodies against MPO (1:1000;
Millipore), 3-nitrotyrosine (1:1000; Millipore),
tubulin (1:1000; Sigma), phospho-paxillin Tyr-118
(1:1000; Cell Signaling), phospho-Src Tyr-416
(1:1000; Cell Signaling), phospho-Src Tyr-527
(1:1000; Cell Signaling), MLC-2 (1:1000; Cell
Signaling) and diphospho-MLC-2 Thr-18/Ser-19
(1:1000; Cell Signaling). Proteins were visualized
in gels by SyproRuby® staining (Invitrogen) and a
Fuji FLA-5000 imaging system.

RESULTS
Endothelial-transcytosed
MPO
accumulates
within the subendothelium where it oxidatively
crosslinks matrix fibronectin in a HOCl-dependent
manner— Incubation of confluent monolayers of
ECs with MPO resulted in its uptake and
accumulation
within
the
subendothelial
compartment, where it co-localized with matrix
fibronectin (FIG. 1A), observations consistent with
a previous study by Baldus et al. (12). ECs
containing
transcytosed
MPO
consumed
exogenously added H2O2 at significantly enhanced
rates compared to control cells (FIG. 1C). Laser
confocal microscopy and immunofluorescence
showed that H2O2 consumption by MPOcontaining ECs was accompanied by the formation
of
HOCl-oxidized
protein
within
the
subendothelial matrix, which co-localized with
matrix fibronectin (FIG. 1B). Western blot
analysis of protein extracts of these cells revealed
extensive fibronectin crosslinking, reflected by
loss of the parent fibronectin band and generation
of non-reducible, high molecular weight (>250
kDa) protein aggregates that were recognized by
antibodies directed against fibronectin and HOCloxidized protein (FIG. 2A). Production of HOCloxidized proteins and fibronectin crosslinking
were absent in control ECs treated with H2O2
alone (FIG. 1B, FIG. 2A). Purified bovine
fibronectin was similarly converted into HOClmodified, high molecular weight aggregates by

Immunofluorescence— Cells on glass coverslips
were processed for immunostaining by fixing with
4% paraformaldehyde (22C, 20 min) and
quenching free aldehydes with NH4Cl (50 mM) for
5 min prior to washing in PBS. Cells were
immunostained
using
mouse
monoclonal
antibodies against fibronectin (1:100), HOCloxidized protein (2D10G9) (1:50) and paxillin
(1:1000) or rabbit polyclonal antibodies against
MPO (1:100) and fibronectin (1:100). Cy24
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exposure to MPO in the presence of H2O2 (FIG.
2B). Inclusion of the MPO inhibitor ABAH or the
HOCl-scavenger methionine (Met) prevented
fibronectin cross-linking and generation of HOCloxidized protein within cells (FIG. 2C) and with
purified fibronectin (FIG. 2D), confirming MPOderived HOCl as the damaging species. Notably,
HOCl
derived
from
low
micromolar
concentrations of H2O2 (10 μM) by endothelialtranscytosed MPO efficiently oxidized matrix
fibronectin, as judged by the loss of the parent
fibronectin band, whilst equivalent doses of
reagent HOCl added as a bolus to the apical
endothelial surface were ineffective (FIG. 2A).
These data establish that transcytosed MPO
mediates targeted matrix oxidation by producing
HOCl focally within the subendothelial
compartment.

transcytosed MPO simultaneously promotes
covalent crosslinking and nitration of matrix
fibronectin in the presence of NO2−, covalent
fibronectin crosslinking is mediated primarily by
HOCl.
MPO disrupts the cell-adhesive function of
fibronectin in a HOCl-dependent manner— We
next addressed the functional consequences of
fibronectin oxidation by MPO, measured by its
ability to support EC attachment and spreading. In
these studies, MPO was first bound to fibronectincoated surfaces, unbound MPO removed by
washing and the MPO-bearing fibronectin surfaces
exposed to H2O2 for 30 min. EC attachment and
spreading on native and MPO-oxidized fibronectin
was then measured in real time using a cellsubstrate impedance electrode.
ECs seeded on native fibronectin in serum-free
media were fully attached and spread within 2 h
(FIG. 4A). Cell-substrate impedance values in
fully-adhered cells, quantified as ‘cell index’ (a
value proportional to the area of cell-matrix
contact (24)), correlated linearly with cell number
and increased with the density of fibronectin
coating (20 g/mL) (Supplementary FIG. 2).
Background EC adhesion levels on surfaces
without
fibronectin
were
negligible
(Supplementary. FIG. 2), confirming that
adhesion was solely dependent on this substrate.
Binding of MPO (20 nM) to approximately
equimolar concentrations of fibronectin (coated at
5 g/ml / 22 nM) prior to cell seeding did not alter
the rate or extent of cell attachment and spreading,
establishing that MPO does not mask fibronectin
motifs that support EC adhesion (FIG. 4A). Pretreatment of the MPO-bearing fibronectin with
low micromolar doses of H2O2 (≤10 μM)
markedly impaired its ability to support
subsequent EC attachment and spreading, with this
loss of adhesive function abrogated by scavenging
HOCl with Met and inhibiting MPO with ABAH
(FIG. 4B). The MPO-dependent impairment of
fibronectin’s cell adhesive function was also
blocked by inclusion of SCN− or partially
attenuated by NO2− (FIG. 4C). In reactions with
NO2−, HOCl scavenging by Met completely
preserved the cell adhesive function of fibronectin
(FIG. 4C), despite the ability of MPO to catalyze
tyrosine nitration of fibronectin under these
conditions (FIGS. 3C, 3D). These findings

Thiocyanate and nitrite suppress HOCl-mediated
fibronectin oxidation by endothelial-transcytosed
MPO— SCN− and NO2− are important
physiological MPO substrates that divert the
enzyme from HOCl production to the generation
of HOSCN and NO2, respectively with SCN−
acting to stimulate (25) and NO2− acting to
suppress (26) MPO catalytic turnover. In line with
their expected effects on MPO turnover, SCN−
(100 μM) accelerated, and NO2− (100 μM)
attenuated H2O2 consumption by ECs containing
transcytosed MPO (Supplementary FIG. 1).
SCN− supplementation inhibited MPO-catalyzed
formation of HOCl-oxidized protein and
fibronectin modification/cross-linking in ECs
(FIG. 3A) and with purified fibronectin (FIG. 3B).
NO2− also blocked the formation of HOCloxidized protein and attenuated fibronectin
modification/crosslinking and promoted the
generation of 3-nitrotyrosine, detected on high
molecular weight protein aggregates, both in ECs
(FIG. 3A) and on purified fibronectin (FIG. 3B).
To identify the oxidant responsible for mediating
fibronectin crosslinking in the presence of NO2−
we added Met, which scavenges HOCl but not
NO2 (27). Inclusion of Met suppressed fibronectin
crosslinking and caused the majority of 3nitrotyrosine reactive protein to shift from high
molecular weight aggregated material to a single
band that co-migrated with the parent fibronectin
band, both in ECs (FIG. 3C) and with purified
fibronectin (FIG. 3D). Thus, while endothelial5
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fibronectin – Supplementary Movie 1; ECs
containing transcytosed MPO - Supplementary
Movie 2, with representative frames at 0 and 2
min after H2O2 exposure shown in FIG. 6C)
revealed that the losses in cell-matrix contact were
due to rapid membrane retraction and ‘rounding
up’ of cells (i.e. ‘de-adhesion’) and confirmed that
all cells remained attached to the substratum
(Supplementary Movies 1 and 2).
Supplementation of ECs adhered on MPObearing fibronectin with Met or ABAH (FIG. 5B)
and SCN- or NO2- (FIG. 5C) prior to H2O2
exposure attenuated MPO-mediated de-adhesion.
The residual de-adhesion observed in the presence
of SCN- and NO2- was completely prevented by
scavenging spurious amounts of HOCl with Met
(FIG. 5C). Inclusion of Met also completely
abrogated de-adhesion in ECs containing
transcytosed MPO and treated with H2O2 in the
absence or presence of SCN- and NO2- (FIG. 6B).
Overall,
these
data
establish
that
subendothelial-localized MPO triggers cell-matrix
de-adhesion in a HOCl-dependent manner, and
support that this involves disruption of the celladhesive function of fibronectin. Moreover, they
identify that SCN- and NO2- attenuate MPOinduced de-adhesion in accordance with their
capacity to suppress HOCl-mediated damage to
fibronectin (FIG. 3).

establish that covalent modification/crosslinking
of fibronectin by MPO-derived HOCl disrupts its
cell adhesive function and that suppression of
HOCl-mediated oxidative modification by SCN−
and NO2− protects against this loss of function.
Subendothelial MPO induces EC de-adhesion in a
HOCl-dependent manner— Having established
that MPO-derived HOCl disrupts the cell adhesive
function of fibronectin (FIG. 4) and that
fibronectin is an important target for HOCl
produced by subendothelial MPO (FIGS. 1, 2), we
next examined the capacity of endothelialtranscytosed MPO to alter established EC cellmatrix adhesion. To more specifically address the
potential role of fibronectin oxidation by
subendothelial-localized MPO in altering EC cellmatrix adhesion, we performed equivalent studies
with ECs adhered on fibronectin as the sole
adhesive substrate. In these studies, MPO was first
incorporated directly onto fibronectin-coated
surfaces (as detailed in FIG. 4), ECs allowed to
fully adhere for >2 h (cf. FIG. 4A) and changes in
EC adhesion monitored after initiating MPO
activity by exposure to H2O2. Changes in EC cellmatrix adhesion elicited by oxidant production by
transcytosed or fibronectin-bound MPO were
quantified in real time using a cell-substrate
impedance biosensor.
In ECs adhered on MPO-bearing fibronectin,
H2O2 exposure provoked a rapid, time-dependent
(FIG. 5A; p < 0.001 relative to control cells at 2
min at 10 μM H2O2) and dose-dependent (FIG.
5B) loss in cell-matrix contact. Quantification of
ECs adhered to impedance electrodes by Crystal
violet staining revealed that this decrease in cellmatrix contact was independent of changes to the
number of attached cells (Supplementary FIG.
3A). ECs not only maintained cell attachment but
remained viable during oxidant treatment, revealed
by their ability to re-establish adhesion to control
levels following the addition of fresh media
(Supplementary FIG. 3B). A similarly rapid loss
of cell-matrix contact in response to H2O2
exposure was recapitulated in ECs containing
transcytosed MPO (FIG. 6A). No loss of adhesion
was detected in ECs exposed to equivalent doses
of H2O2 in the absence of MPO (FIGS. 5A, 6A).
Live cell imaging of MPO-containing EC exposed
to H2O2 by differential interference contrast (DIC)
microscopy (ECs adhered on MPO-bearing

EC de-adhesion induced by subendothelial MPO
is linked with HOCl-dependent changes in focal
adhesion and cytoskeletal signaling— Cell-matrix
adhesion involves the assembly of membrane
domains called focal adhesions that co-ordinate
cellular responses to local changes in the chemical
and physical state of the extracellular matrix by
transducing ‘outside-in’ signaling (28,29).
Phosphorylation of the focal adhesion protein
paxillin at Tyr-118 has emerged as a major
mechanobiological signaling ‘switch’ that
regulates responses to changes in cell-matrix
adhesion, with loss of force transduction between
the cell membrane and underlying matrix upregulating paxillin phosphorylation at this amino
acid site (30). Also, phosphorylation of myosin
light chain II (MLC-2) at Thr-18 and Ser-19,
which
positively
regulates
actomyosin
contractility, plays a central role in the remodeling
of the cytoskeleton and adhesive contacts in
response to external stimuli (30,31). Therefore, we
6
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next investigated the extent to which matrix
oxidation and disruption of cell-matrix adhesion
by endothelial-localized MPO was linked with
changes in the phosphorylation status of paxillin
and MLC-2.
Exposure of MPO-containing ECs to H2O2 at
≥10 μM triggered a time-dependent increase in the
phosphorylation of paxillin at Tyr-118 that was
apparent after 2 min oxidant addition and
maintained up until 15 min before returning to
baseline levels at 30 min (FIGS. 7A, B). Exposure
of MPO-containing ECs to lower H2O2 doses (5
μM), where EC adhesion was largely maintained
(FIG. 6A), resulted in a time-dependent decrease
in paxillin Tyr-118 phosphorylation (FIG. 7B). No
alteration in paxillin phosphorylation was
observed in control ECs exposed to equivalent
doses of H2O2 in the absence of MPO (FIG. 7A).
The dose-dependent modulation of paxillin
phosphorylation by MPO (i.e., down-regulation at
low oxidant dose or up-regulation at higher
oxidant dose) was prevented by Met and
suppressed in the presence of SCN- and NO2- plus
Met (FIGS. 7C), identifying HOCl as the primary
signaling oxidant produced by EC-localized MPO.
Tyr-118 of paxillin is a phosphorylation target
for FAK or Src kinase (32). In MPO-containing
ECs exposed to H2O2, while no marked change in
Tyr-397 phosphorylated and hence activated FAK
was apparent (FIG. 7A), exposure of these cells to
25 μM H2O2 resulted in the time-dependent
increase in phosphorylation of Src at its
activation/auto-phosphorylation site Tyr-416 that
paralleled the time-dependent increase in paxillin
Tyr-118 phosphorylation (FIGS. 7A, C).
Activation of Src by Tyr-416 phosphorylation can
involve de-phosphorylation of an inhibitory
phosphorylation site (Tyr-527) (33). Src Tyr-416
phosphorylation
and
paxillin
Tyr-118
phosphorylation in MPO-containing ECs exposed
to 25 μM H2O2 were not initially linked with Src
Tyr-527 de-phosphorylation, however decreases in
Tyr-527 phosphorylation were observed after 15 30 min (FIG. 7C). Src Tyr-416 phosphorylation
and Tyr-527 de-phosphorylation were both
prevented by Met and suppressed in the presence
of SCN− or NO2− plus Met (FIG. 7C). A role of
Src kinase for HOCl-dependent paxillin
phosphorylation was indicated by the ability of the
Src kinase inhibitor PP2 to block both basal and

MPO-induced paxillin Tyr-118 phosphorylation
(FIG. 7D).
With respect to myosin II signaling, exposure
of MPO-containing ECs to H2O2 resulted in the
dose- (FIG. 7A) and time-dependent (FIG. 7B)
increase in the cellular levels of di-phosphorylated
MLC-2 (Tyr-18/Ser-19). MPO-induced MLC-2
phosphorylation was inhibited by addition of Met
or SCN- or NO2- plus Met (FIG. 7C), confirming
its dependence on HOCl, and was prevented by
inhibiting Rho kinase with Y-27632 (FIG. 7E). Y27632 did not suppress HOCl-mediated
fibronectin oxidation, confirming that its activity
reflected its action as a Rho kinase inhibitor (FIG.
7E).
EC de-adhesion induced by subendothelial MPO
is dependent on actomyosin contractility— The
preceding studies identify that HOCl produced by
subendothelial-localized MPO elicits Rho kinasedependent MLC-2 phosphorylation, which signals
for increased myosin II-dependent contractility,
and alters Src-dependent paxillin phosphorylation.
We next examined the potential functional role of
these signaling events in MPO-induced deadhesion by employing pharmacological inhibitors
of myosin II signaling and Src-dependent paxillin
phosphorylation. Changes in EC adhesion were
quantified over time by cell-substrate impedance
and/or by measuring decreases in the projected
area of individual cells by image analysis of timelapse DIC movies.
Src inhibition with PP2 had no impact on the
rate of MPO-induced de-adhesion (FIG. 8B),
indicating that while Src-dependent paxillin
phosphorylation is a signaling response linked
with de-adhesion it does not directly contribute to
it. In contrast, inhibition of myosin II motor
function with blebbistatin markedly abrogated
membrane retraction from the substratum and
from adjacent cells in MPO-containing ECs
exposed to H2O2, both in ECs containing
transcytosed MPO (FIG. 8A-D) and in ECs
adhered
on
MPO-bearing
fibronectin
(Supplementary FIGS. 4A-D) (see also
Supplementary Movies 1-4 for representative
time-lapse DIC movies used for image analysis).
Blebbistatin prevented EC de-adhesion without
inhibiting HOCl-mediated fibronectin oxidation or
MLC-2 phosphorylation (FIG. 7E), confirming
7
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that its inhibitory activity reflected its action as an
inhibitor of myosin II motor function.
The rates of membrane retraction in individual
cells during MPO-induced de-adhesion (measured
as decreases in projected cell area over time) were
quite uniform, with losses in cell area plateauing at
ca. 50% of initial values and cells exhibiting
average contraction half-lives of ca. 1 – 2 min both
in ECs containing transcytosed MPO (FIGS. 8C,
D) and in ECs adhered on MPO-bearing
fibronectin (Supplementary FIGS. 4C, D). Of
note, robust increases in Rho kinase-dependent
MLC-2 phosphorylation occurred only after 5 min,
when membrane retraction was already extensive
(FIG. 7B). Furthermore, Rho kinase inhibition (Y27632) did not suppress the initial rapid phase of
de-adhesion (<5 min following H2O2 exposure)
and was protective only during the subsequent
phase of de-adhesion (>5 min following H2O2
exposure) (FIGS. 8A, B) when Rho kinasedependent MLC-2 phosphorylation was increased
(cf. FIG. 7B).
Staining of MPO-containing ECs for F-actin
and paxillin prior to (Supplementary FIG. 5A)
and 10 min following H2O2 exposure
(Supplementary FIG. 5B) showed that deadhesion involved extensive inward remodeling of
the actin cytoskeleton and accumulation of F-actin
and paxillin at the membrane periphery, with these
effects abrogated by HOCl scavenging with Met
(Supplementary FIG. 5C). Although Rho kinasedependent MLC-2 phosphorylation peaked within
5 – 15 min following H2O2 exposure (FIG. 7B),
this was not accompanied by an increase in long
actin stress fibres and instead de-adhesion was
characterized by a loss of pre-existing stress fibres
(Supplementary FIGS. 5A, B).
Overall, these findings support that while upregulation of Rho kinase-dependent contractility
contributes to the overall extent of MPO-induced
de-adhesion, the initial, rapid phase of membrane
retraction represents a response to oxidative
disruption of cell-matrix contacts by MPO-derived
HOCl, and is primarily driven by pre-existing
stress in the actin cytoskeleton.

the subendothelial extracellular matrix by binding
to and transcytosing the endothelium (12,19).
Compelling clinical and experimental evidence
has identified endothelial-transcytosed MPO as a
key mediator of impaired NO signaling in
inflammatory vascular responses and in human
cardiovascular disease, with this thought to reflect
its ability to efficiently intercept and oxidatively
consume endothelial-derived NO within the
subendothelial
space
(7,10,11).
However,
subendothelial-localized MPO is also anatomically
positioned to impact on endothelial morphology
and signaling by oxidatively modifying the
structure and function of adhesive extracellular
matrix proteins (12,15,16).
This study shows for the first time that
subendothelial-localized MPO utilizes low
micromolar concentrations of H2O2 to mediate
targeted, HOCl-dependent oxidation of the
subendothelial matrix, with this involving covalent
modification/crosslinking of matrix fibronectin.
Employing real time cell-substrate impedance
biosensor measurements and quantitative live cell
image analysis, we showed that HOCl-mediated
oxidation of the subendothelial matrix triggers
rapid retraction of the cell membrane from the
substratum and from adjacent ECs (de-adhesion).
EC de-adhesion was linked with the activation of
Src and modulation of Tyr-118 phosphorylation of
paxillin, a key focal adhesion-dependent signaling
process, as well as Rho kinase-dependent MLC-2
phosphorylation. Of these signaling events, MPOinduced EC de-adhesion were dependent on the
actomyosin contractile machinery as inhibition of
myosin II and Rho kinase-mediated MLC-2
phosphorylation significantly reduced the overall
rate of membrane retraction.
Previous studies have shown that transcytosed
MPO associates basolaterally with fibronectin and
locally catabolizes NO2- to the nitrating radical
NO2, conferring specificity of MPO-mediated
protein tyrosine nitration to fibronectin (12).
Immunohistochemical studies support that
fibronectin is an important target for MPO-derived
NO2 in inflammatory vascular disorders, with
MPO, fibronectin and tyrosine nitrated proteins
having been shown to co-localize in diseased
human vessels (19). However, the functional
implications of NO2 production within the
endothelium by MPO have not been previously
investigated. The current study reveals that in the

DISCUSSION
During vascular inflammation, MPO is released
from activated leukocytes and accumulates within
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presence
of
NO2subendothelial
MPO
concomitantly
catalyzes
HOCl-dependent
crosslinking and tyrosine nitration of matrix
fibronectin. However, HOCl-mediated reactions
were shown to be primarily responsible for
triggering EC de-adhesion and associated cell
signaling events: Scavenging of HOCl with Met
markedly attenuated fibronectin crosslinking and
cell signaling responses, but did not prevent
fibronectin nitration.
Another biologically important MPO substrate
is SCN−, which is derived primarily from dietary
sources (e.g., broccoli) and is elevated in smokers.
Currently, there is considerable interest in whether
diversion of MPO from HOCl production by SCN−
to instead produce the thiol-reactive oxidant
HOSCN is protective or deleterious in the context
of inflammatory vascular conditions (34,35). Our
finding that SCN- accelerates H2O2 metabolism yet
suppresses HOCl production by EC-localized
MPO is indicative of local production of HOSCN.
Despite this, SCN− supplements were protective
against MPO-induced EC de-adhesion and
associated signaling responses, indicating the
HOSCN produced by subendothelial MPO is
functionally silent in this regard. These findings
are consistent with other findings that identify a
protective, antioxidant function for SCN− against
MPO-mediated EC injury (34).
Model studies employing purified fibronectin
as the sole adhesive substrate provided strong
evidence that induction of EC de-adhesion by
MPO-derived HOCl involves disruption of the
cell-adhesive function of fibronectin. Thus,
oxidation of fibronectin by MPO-derived HOCl
readily impaired its ability to support EC
attachment and spreading and this loss in function
correlated well with the capacity of HOCl,
produced at the basolateral surface of ECs by
fibronectin-bound MPO, to disrupt established EC
adhesion on fibronectin. In accordance with their
ability to suppress HOCl-mediated fibronectin
modification/crosslinking, SCN− and NO2−
prevented MPO-induced impairment of attachment
and spreading of ECs on, and de-adhesion of ECs
from fibronectin.
Whilst our data identify a causal role for
HOCl-mediated matrix oxidation in triggering EC
de-adhesion, we showed that actomyosin tensile
forces significantly accelerate this process. Thus,
the rate of de-adhesion triggered by H2O2 exposure

in MPO-containing ECs was markedly attenuated
by the inhibition of myosin II motor function with
blebbistatin. Up-regulation of Rho kinasedependent contractility contributed to the MPOinduced EC de-adhesion, but not during the initial
rapid phase of membrane retraction, which
preceded robust increases in Rho kinasedependent MLC-2 phosphorylation and was not
attenuated by Rho kinase inhibition.
Our data support a model where
subendothelial-localized MPO catalyzes targeted,
HOCl-mediated matrix oxidation that disrupts
adhesive forces at the cell-matrix interface to
trigger membrane retraction driven by pre-existing
tensile force within the actin cytoskeleton
(SCHEME 1A, B). Notably, other recent studies
identify that targeted disruption of cell-matrix
contacts by electrochemical means likewise
provokes rapid cell contraction driven by preexisting actomyosin tensile stress (36).
As well as mechanically coupling the actin
cytoskeleton to the subendothelial matrix,
adhesive contacts are enriched in cytoplasmic
signaling proteins and rapidly transduce
mechanical signals provided by changes in cellmatrix adhesion into intracellular phosphorylation
events. This ‘outside-in’ signaling, in which
paxillin phosphorylation plays a central regulatory
role, allows cells to respond rapidly and
sensitively to chemical and physical changes in the
extracellular matrix and engages signaling
networks that control cell shape, motility,
proliferation and survival (28-31).
We propose that the focal disruption of cellmatrix contacts by HOCl in the subendothelium
drives signaling changes by altering cell-matrix
mechanotransduction (SCHEME 1C). Paxillin Tyr118 phosphorylation is negatively regulated by
force transduction at focal adhesions (i.e. cellmatrix traction) (30) and the increase in
phosphorylation observed at this site at higher
oxidant doses is fully consistent with a global loss
in cell-matrix traction triggered by HOClmediated matrix oxidation. Phosphorylation of
paxillin at Tyr-118 generates docking sites for
SH2 domain containing proteins (29) and engages
signaling networks that regulate the assembly of
new adhesive contacts (30). Notably, the levels of
paxillin phosphorylation were initially maintained
and chronically down-regulated during deadhesion at lower oxidant doses, where matrix
9
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oxidation and de-adhesion was less extensive, with
this consistent with compensatory increases in
cell-matrix traction at pre-existing and/or newly
formed adhesive contacts (30).
Another important novel aspect of this work is
the finding that HOCl produced subendothelially
by MPO induces Rho kinase-dependent MLC-2
di-phosphorylation at Tyr-18 and Ser-19, and Src
activation as indexed by Tyr-416 phosphorylation
and Tyr-527 de-phosphorylation. Together with
alterations in paxillin phosphorylation, MLC-2
phosphorylation and Src activation represent key
signaling processes involved in adhesion
responses (30,31). The specificity of these
responses to the action of MPO-derived HOCl
indicates that they may be functionally linked to
changes in cell-matrix mechanotransduction (see
discussion below). Notably, previous studies
identify that loss of cell adhesion alone can trigger
increases in Src activation and paxillin
phosphorylation (37,38).
Significantly, no previous study has addressed
the possibility that oxidants might drive changes in
cell
signaling
by
altering
cell-matrix
mechanotransduction. Our proposed model of
‘outside-in’ redox signaling (SCHEME 1) differs
from the conventional model of redox signaling in
that it involves oxidants modifying extracellular
proteins and generating mechanical signals to
propagate intracellular phosphorylation events
instead of directly modifying and altering the
activity of intracellular signaling proteins.
We do not exclude that ‘conventional’ redox
signaling mechanisms contribute to the signaling
responses elicited by subendothelial-localized
MPO. HOCl could contribute to the observed
signaling
responses
(paxillin
Tyr-118
phosphorylation, Src Tyr-118 phosphorylation/
Tyr-527 de-phosphorylation or MLC-2 Tyr-18/
Ser-19 phosphorylation), by directly oxidizing
critical cysteine residues present on RhoA (which
activates Rho kinase) and Src, leading to their
activation (33,39,40) or by oxidizing active site
cysteines in regulatory protein phosphatases.
However, given that HOSCN is predominantly a
thiol-selective oxidant (18), the ability of SCN- to
suppress these signaling responses is not
consistent with a role for conventional redox
signaling as if the case the formation of HOSCN
by EC-localized MPO would also be expected to

promote
the
relevant
signaling
events.
Furthermore, kinetic considerations on the
reactivity of oxidants predicts that HOCl exerts its
biological effects by oxidizing targets within a
very short distance of its site of production (41). In
line with this prediction, our current data identifies
that HOCl produced by endothelial-transcytosed
MPO mediates focal oxidation of matrix proteins
within the subendothelial compartment to alter
adhesion and adhesion-dependent signaling. We
propose that this involves HOCl-mediated
impairment of the function of the cell-adhesion
(integrin- and/or heparin-binding) motifs of
fibronectin. Indeed, the lack of cysteine and
tyrosine residues in these adhesion motifs, and
hence their resistance to functional damage by
HOSCN and NO2, could explain why diversion of
MPO from HOCl production by SCN- and NO2was protective against de-adhesion and associated
signaling responses.
Physiological redox signaling processes are
increasingly recognized to be highly regulated,
involving targeted, oxidative modification of
specific proteins, with signaling specificity
achieved through spatial association of oxidantgenerating enzymes and target proteins within
specific
cellular
compartments
(1,42).
Interestingly, the alteration of endothelial
signaling by subendothelial matrix-bound MPO
fits within this paradigm. It is therefore tempting
to speculate that the delivery of MPO to the
subendothelial compartment by endothelialtranscytosis to promote HOCl-mediated matrix
oxidation might serve an unforseen regulatory
function during inflammatory vascular responses.
However, its potential pathophysiological
significance is clear: Our present findings identify
that matrix oxidation resulting from the production
of low, physiological fluxes of HOCl by
subendothelial-localized MPO triggers a rapid loss
in endothelial cell-matrix adhesion and increase in
membrane retraction, events that will significantly
perturb the integrity of the endothelium. These
processes could play a key pathological role in
inflammatory vascular conditions by promoting
tissue oedema and compromising the antiinflammatory/anti-thrombogenic function of the
endothelium by exposing intimal proteins.
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FIGURE LEGENDS
FIGURE 1. Endothelial-transcytosed MPO localizes with matrix fibronectin and mediates HOCldependent protein oxidation. EC monolayers were incubated with MPO (20 nM) for 2 h and
unincorporated MPO removed by washing. MPO-containing ECs were then incubated with H2O2 (50 μM)
for a further 1 h. (A) MPO-containing ECs prior to H2O2 treatment were fixed and imaged by laser
confocal fluorescence microscopy using antibodies against fibronectin (FN; green) or MPO (red). (B)
MPO-containing ECs treated with H2O2 were fixed and imaged by laser confocal fluorescence
microscopy using antibodies against fibronectin (FN; green) or HOCl-oxidized protein (clone 2D10G9;
red). Nuclei were counterstained with DAPI (blue). Bar = 50 m. (C) H2O2 consumption by control and
MPO-containing ECs over 1 h was measured by assaying cell supernatants by the Amplex Red assay at
the indicated times. Data represent the mean  SEM, n = 3 independent experiments, ** = p < 0.01
relative to control cells.
FIGURE 2. Endothelial-transcytosed MPO oxidatively crosslinks matrix fibronectin in a HOCldependent manner. (A, B) EC monolayers were incubated with MPO (20 nM) for 2 h and
unincorporated MPO removed by washing. Control and MPO-containing ECs were non-treated or treated
with H2O2 (1-50 μM) for 1 h in the absence and presence of Met (1 mM) or ABAH (100 μM). In (A),
control ECs were also treated with a bolus of reagent HOCl (10 μM) for 1 h. (C, D) Purified bovine
fibronectin (100 nM) was pre-incubated with MPO (100 nM) for 15 min) prior to addition of H2O2 (0 - 50
μM) and incubation for a further 1 h in the absence and presence of Met (1 mM) or ABAH (100 μM).
Cell proteins and purified proteins were analyzed by Western blotting (3-8% gels) under reducing
conditions using antibodies against fibronectin (FN) or HOCl-oxidized protein (clone 2D10G9). In (A),
tubulin (55 kDa) was used as a protein loading control. In (C), protein bands of the purified proteins were
visualized in the gels by Syproruby® staining (i.e., native FN monomer detected at 250 kDa and MPO chain monomer detected at ~60 kDa). Western blot/gel images are reduced by 50% on the vertical scale.
FIGURE 3. Thiocyanate and nitrite suppress HOCl-mediated fibronectin oxidation by endothelialtranscytosed MPO. (A, B) EC monolayers were incubated with MPO (20 nM) for 2 h and
unincorporated MPO removed by washing. Control and MPO-containing ECs were then non-treated or
treated with H2O2 (50 μM) for 1 h in the absence and presence of SCN− (100 μM), NO2− (100 μM) or Met
(1 mM). (C, D) Purified bovine fibronectin (FN; 100 nM) was incubated with MPO (100 nM, 15 min),
then non-treated or treated with H2O2 (50 μM) for 1 h in the absence and presence of SCN− (100 μM),
NO2- (100 μM) or Met (1 mM). (A, B) Cell proteins or (C, D) purified proteins were analyzed by Western
blotting (3-8% gels) using antibodies against FN, HOCl-oxidized protein (clone 2D10G9) or 3nitrotyrosine (NO2Tyr). Western blot/gel images are reduced by 50% in the vertical scale.
FIGURE 4. MPO-derived HOCl impairs the cell-adhesive function of fibronectin. Bovine fibronectin
was coated at 5 g/ml (ca. 22 nM) and incubated with MPO (20 nM) for 30 min before unbound MPO
was removed by washing. Fibronectin and MPO-bearing fibronectin surfaces were then non-treated or
treated with H2O2 (1-10 μM) for 1 h in the absence and presence of Met (1 mM), ABAH (100 μM), SCN−
(100 μM) or NO2− (100 μM). Met (10 mM, 10 min) was then added to quench chloroamines, surfaces
washed and ECs seeded. EC adhesion and spreading was then measured 2 h after cell seeding by cellsubstrate impedance. (A) EC adhesion onto fibronectin (control) or MPO-bearing fibronectin (MPO)
(without H2O2 pre-treatment) over the 2 h period after cell seeding. (B) EC adhesion (2 h post-seeding) on
non-treated or H2O2-treated fibronectin or MPO-bearing fibronectin in the absence and presence of Met or
ABAH. (C) EC adhesion (2 h post-seeding) on MPO-bearing fibronectin treated with H2O2 in the absence
and presence of SCN−, NO2− and/or Met. Data represent the mean  SEM, n = 3. *** = p < 0.001 relative
to EC adhesion onto MPO-bearing fibronectin without H2O2 treatment. # = p < 0.05.
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FIGURE 5. Subendothelial MPO induces EC de-adhesion from fibronectin in a HOCl-dependent
manner. Bovine fibronectin was coated at 5 g/ml (ca. 22 nM) and incubated with MPO (20 nM) for 30
min before unbound MPO was removed by washing. ECs were seeded and allowed to fully adhere over 2
h onto fibronectin and MPO-bearing fibronectin surfaces (cf. Fig. 4A) before non-treatment or treatment
with H2O2 (1-10 μM) in the absence and presence of Met (1 mM), ABAH (100 μM), SCN− (100 μM) or
NO2− (100 μM). Oxidant-induced changes in cell adhesion were measured by cell-substrate impedance
over the ensuing 30 min after H2O2 addition; cell index data is normalized to the cell index value at the
time of H2O2 addition which was given a value of 1. (A) Time-dependent changes in cell adhesion of ECs
pre-adhered onto fibronectin (control) or MPO-bearing fibronectin (MPO) and then non-treated or treated
with H2O2 (10 μM). (B) Cell adhesion of ECs pre-adhered onto fibronectin or MPO-bearing fibronectin
following 30 min treatment with H2O2 (1-10 μM) in the absence or presence of Met or ABAH. (C) Cell
adhesion of ECs pre-adhered onto MPO-FN following 30 min after treatment with H2O2 in the absence or
presence of SCN−, NO2− and NO2−/Met. Data represent the mean  SEM, n = 6 (A) or n = 3 (B, C). * = p
< 0.05, ** = p < 0.01 and *** = p < 0.001 relative to cell adhesion changes of MPO-containing ECs
without H2O2 treatment. # = p < 0.05.
FIGURE 6. Endothelial-transcytosed MPO induces EC de-adhesion in a HOCl-dependent manner.
EC monolayers were incubated with MPO (20 nM) for 2 h and unincorporated MPO removed by
washing. Control and MPO-containing ECs were then non-treated or treated with H2O2 (5 or 25 μM) in
the absence and presence of Met (1 mM), SCN− (100 μM) or NO2− (100 μM). Oxidant-induced changes to
cell adhesion were then measured by cell-substrate impedance; cell index data is normalized to the cell
index value at the time of H2O2 addition which was given a value of 1. (A) Time-dependent changes in
cell adhesion of control or MPO-containing ECs following treatment with the indicated concentrations of
H2O2. (B) Cell adhesion changes of MPO-containing ECs after 30 min treatment with H2O2 in the absence
or presence of Met, SCN−, NO2− or Met/NO2−. Data represent the mean  SEM, n = 6. *** = p < 0.001
relative to MPO-containing ECs without H2O2 exposure. # = p < 0.05. (C) Frames from a representative
live cell DIC microscopy movie (Supplementary Movie 2) of MPO-containing ECs before (0 min) and
after treatment with H2O2 (10 μM) for 2 min. Bar = 50 m.
FIGURE 7. Endothelial-transcytosed MPO alters the phosphorylation of paxillin, Src and MLC-2 in
a HOCl-dependent manner. (A-E) EC monolayers were incubated with MPO (20 nM) for 2 h and
unincorporated MPO removed by washing. Control and MPO-containing ECs were then treated with
H2O2 (2 - 25 μM) in the absence or presence of other reaction components (1 mM Met, 100 μM ABAH,
100 μM SCN- or 100 μM NO2-) or selective inhibitors of myosin II (blebbistatin, 40 μM), Rho kinase (Y27632, 10 μM) or Src kinase (PP2, 20 μM). At the indicated times after the addition of H2O2, cellular
protein extracts were prepared and analyzed by Western blotting for the levels of fibronectin (FN),
paxillin Tyr-118 phosphorylation, paxillin, Src Tyr-416 or Tyr-527 phosphorylation, Src, FAK Tyr-397
phosphorylation, FAK, MLC-2 Tyr-18/Ser-19 di-phosphorylation and MLC-2.
FIGURE 8. EC de-adhesion induced by endothelial-transcytosed MPO involves myosin II-mediated
contractility. EC monolayers were incubated with MPO (20 nM) for 2 h and unincorporated MPO
removed by washing. MPO-containing ECs were then treated with H2O2 (10 μM) for 15 min in the
absence or presence of inhibitors of myosin II (blebbistatin, 40 μM), Rho kinase (Y-27632, 10 μM) or Src
kinase (PP2, 20 μM). (A, B) Changes in cell adhesion, measured by cell-substrate impedance, in MPOcontaining ECs after treatment with H2O2 in the absence or presence of blebbistatin, Y-27632 or PP2. (B)
EC adhesion 15 min after H2O2 addition. Data represent the mean  SEM, n = 6. Cell index data is
normalized to the cell index value at the time of H2O2 addition which was given a value of 1. (C, D)
Changes in cell area, measured by image analysis of time-lapse DIC microscopy movies, in MPOcontaining ECs after treatment with H2O2 in the absence or presence of blebbistatin (n = 10 cells, 2
replicate movies, 5 randomly selected cells per movie - cf. Supplementary Movies 2 and 4); cell area
14
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data are normalized to the cell area value at the time of H2O2 addition which was given a value of 1. (C,
inset) cell contraction half-lives determined by fitting the data to a single exponential decay to cell area
values in individual cells over time. (D) Cell area, expressed as m2, before (0 min) and 13 min after
H2O2 addition. *** = p < 0.001 relative to MPO-containing ECs (B) without or (D) prior to H2O2
exposure. # = p < 0.05.
SCHEME 1. Proposed model of MPO-induced EC de-adhesion and ‘outside-in’ redox signaling. (A)
MPO binds to the subendothelial matrix and mediates targeted HOCl-dependent matrix oxidation that (B)
disrupts cell-matrix contact, leading to (C) membrane retraction driven by unopposed tension in the actin
cytoskeleton and alteration of adhesion-dependent signaling. ‘pax’ = paxillin.
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